Black Sun Bio-Weapons – 3 – AstraZeneca COVID-19 Vaccine [UK]



COVID-19 Vaccine

The Official Story

(AstraZeneca, UK)


The Oxford–AstraZeneca COVID 19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for prevention of COVID-19. Developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose, and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant (lineage B.1.1.7), and 61% against the Delta variant (lineage B.1.617.2).

The vaccine is stable at refrigerator temperatures and has a good safety profile, with side effects including injection-site pain, headache, and nausea, all generally resolving within a few days. More rarely, anaphylaxis may occur; the UK Medicines and Healthcare products Regulatory Agency (MHRA) has 268 reports out of some 21.2 million vaccinations as of 14 April 2021. In very rare cases (around 1 in 100,000 people) the vaccine has been associated with an increased risk of blood clots when in combination with low levels of blood platelets (Embolic and thrombotic events after COVID-19 vaccination). According to the European Medicines Agency as of 4 April 2021, a total of 222 cases of extremely rare blood clots had been recorded among 34 million people who had been vaccinated in the European Economic Area (a percentage of 0.0007%).

On 30 December 2020, the vaccine was first approved for use in the UK vaccination programme, and the first vaccination outside of a trial was administered on 4 January 2021. The vaccine has since been approved by several medicine agencies worldwide, such as the European Medicines Agency (EMA), and the Australian Therapeutic Goods Administration (provisional approval in February 2021), and was approved for an Emergency Use Listing by the World Health Organization (WHO). As of January 2022, more than 2.5 billion doses of the vaccine have been released to more than 170 countries worldwide. Some countries have limited its use to elderly people at higher risk for severe COVID-19 illness due to concerns over the very rare side effects of the vaccine in younger individuals.


The Oxford–AstraZeneca COVID-19 vaccine is a viral vector vaccine containing a modified, replication-deficient chimpanzee adenovirus ChAdOx1, containing the full‐length codon‐optimised coding sequence of SARS-CoV-2 spike protein along with a tissue plasminogen activator (tPA) leader sequence. The adenovirus is called replication-deficient because some of its essential genes required for replication were deleted and replaced by a gene coding for the spike protein. However, the HEK 293 cells used for vaccine manufacturing, express several adenoviral genes, including the ones required for the vector to replicate. Following vaccination, the adenovirus vector enters the cells and releases its genes, in the form of DNA, which are transported to the cell nucleus; thereafter, the cell’s machinery does the transcription from DNA into mRNA and the translation into spike protein. The approach to use adenovirus as a vector to deliver spike protein is similar to the approach used by the Johnson & Johnson COVID-19 vaccine and the Russian Sputnik V COVID-19 vaccine.

The protein of interest is the spike protein, a protein on the exterior of the virus that enables SARS-type coronaviruses to enter cells through the ACE2 receptor. Following vaccination, the production of coronavirus spike protein within the body will cause the immune system to attack the spike protein with antibodies and T-cells if the virus later enters the body.


The first country to issue a temporary or emergency approval for the Oxford–AstraZeneca vaccine was the UK. The Medicines and Healthcare products Regulatory Agency (MHRA) began a review of efficacy and safety data on 27 November 2020, followed by approval for use on 30 December 2020, becoming the second vaccine approved for use in the national vaccination programme. The BBC reported that the first person to receive the vaccine outside of clinical trials was vaccinated on 4 January 2021.

The European Medicines Agency (EMA) began review of the vaccine on 12 January 2021, and stated in a press release that a recommendation could be issued by the agency by 29 January, followed by the European Commission deciding on a conditional marketing authorisation within days. On 29 January 2021, the EMA recommended granting a conditional marketing authorisation for AZD1222 for people 18 years of age and older, and the recommendation was accepted by the European Commission the same day. Prior to approval across the EU, the Hungarian regulator unilaterally approved the vaccine instead of waiting for EMA approval.

On 30 January 2021, the Vietnamese Ministry of Health approved the AstraZeneca vaccine for use, becoming the first vaccine to be approved in Vietnam. The vaccine has since been approved by a number of non-EU countries, including Argentina, Bangladesh, Brazil, the Dominican Republic, El Salvador, India, Israel, Malaysia, Mexico, Nepal, Pakistan, the Philippines, Sri Lanka, and Taiwan regulatory authorities for emergency usage in their respective countries.

South Korea granted approval of the AstraZeneca vaccine on 10 February 2021, thus becoming the first vaccine to be approved for use in that country. The regulator recommended the two-shot regimen be used in all adults, including the elderly, noting that consideration is needed when administering the vaccine to individuals over 65 years of age due to limited data from that demographic in clinical trials. On the same day, the World Health Organization (WHO) issued interim guidance and recommended the AstraZeneca vaccine for all adults, its Strategic Advisory Group of Experts also having considered use where variants were present and concluded there was no need not to recommend it.

In February 2021, the government and regulatory authorities in Australia (16 February 2021) and Canada (26 February 2021) granted approval for temporary use of the vaccine.

On 19 November 2021, the vaccine was approved for use in Canada.

Source: Wikipedia


(Star Trek: First Contact, 1996)


Oxford–AstraZeneca COVID-19 Vaccine

The Oxford–AstraZeneca COVID-19 vaccine, sold under the brand names Vaxzevria and Covishield, is a viral vector vaccine produced by the British University of Oxford, British-Swedish company AstraZeneca, and the Coalition for Epidemic Preparedness Innovations. Finland, Denmark, and Norway suspended the use of the Oxford–AstraZeneca vaccine due to a small number of reports of a rare blood clot disorder. Slovakia suspended its use after the death of a predisposed recipient. South Africa suspended its use because a small trial found only minimal protection against mild to moderate disease from the locally predominant Beta variant. Japan approved the vaccine for emergency use in May 2021, but did not plan to use them immediately because of rare cases of a blood clotting disorder reported overseas. Later, Japan started to use the vaccine for people aged 40 or over to mitigate the surge of the Delta variant in August. Finland ceased use of the vaccine as the last batch expired on 30 November 2021. Until then it was only offered for those aged 65 or more due to extremely rare coagulation disorders among younger recipients of the vaccine. After this Finland will not procure more of the vaccine. The AstraZeneca vaccine is the most widely accepted internationally, and the most popular in terms of total inoculated worldwide, over 1.3 billion. The AstraZeneca vaccine is administered in more countries than any other vaccine.

Oxford–AstraZeneca Worldwide Authorizations

GLOBAL GENOCIDE 2025 (Click Links Below)

Emergency (EMA countries)

  1. Austria
  2. Belgium
  3. Bulgaria
  4. Croatia
  5. Cyprus
  6. Czech Republic
  7. Denmark
  8. Estonia
  9. Finland
  10. France
  11. Germany
  12. Greece
  13. Hungary
  14. Iceland
  15. Ireland
  16. Italy
  17. Latvia
  18. Liechtenstein
  19. Lithuania
  20. Luxembourg
  21. Malta
  22. Netherlands
  23. Norway
  24. Poland
  25. Portugal
  26. Romania
  27. Slovakia
  28. Slovenia
  29. Spain
  30. Sweden

CARPHA countries

  1. Antigua and Barbuda
  2. Bahamas
  3. Barbados
  4. Belize
  5. Dominica
  6. Grenada
  7. Guyana
  8. Haiti
  9. Jamaica
  10. Saint Kitts and Nevis
  11. St. Lucia
  12. St. Vincent and the Grenadines
  13. Suriname
  14. Trinidad and Tobago

Non-country entities

  • Anguilla
  • Aruba
  • British Virgin Islands
  • Bermuda
  • Caribbean Netherlands
  • Cayman Islands
  • Curaçao
  • Cook Islands
  • Falkland Islands
  • French Polynesia
  • Greenland
  • Guadeloupe
  • Guernsey
  • Isle of Man
  • Jersey
  • Montserrat
  • Northern Cyprus
  • Pitcairn
  • Saint Helena, Ascension and Tristan da Cunha
  • Sint Maarten
  • Turks and Caicos Islands
  • Wallis and Futuna
  • World Health Organization



The Truth


A false flag is a covert operation designed to deceive; the deception creates the appearance of a particular party, group, or nation being responsible for some activity, disguising the actual source of responsibility.


(of a stimulus or mental process) below the threshold of sensation or consciousness; perceived by or affecting someone’s mind without their being aware of it.





The mass murder of Jews under the German Nazi regime during the period 1941–5. More than 6 million European Jews, as well as members of other persecuted groups, were murdered at concentration camps such as Auschwitz.



Comments are closed.